8-K: Dexcom Reports Strong Q1 2025 Results, Announces $750 Million Share Repurchase Program

Dexcom's Q1 2025 revenue grew 12% year-over-year to $1.036 billion, with the company also announcing a $750 million share repurchase program.

Summary

• Dexcom reported its financial results for the quarter ended March 31, 2025.
• Worldwide revenue grew 12% to $1.036 billion, compared to $921.0 million in the first quarter of 2024.
• U.S. revenue increased by 15%, while international revenue grew by 7%.
• GAAP operating income was $133.7 million, representing 12.9% of revenue.
• Non-GAAP operating income was $143.1 million, or 13.8% of revenue.
• GAAP net income was $105.4 million, or $0.27 per diluted share.
• Non-GAAP net income was $127.7 million, or $0.32 per diluted share.
• Dexcom held $2.70 billion in cash, cash equivalents, and marketable securities as of March 31, 2025.
• The company's Board of Directors authorized a share repurchase program of up to $750.0 million.
• Dexcom is updating fiscal year 2025 guidance for Non-GAAP Gross Profit Margin, and reiterating guidance for Revenue, Non-GAAP Operating Margin, and Adjusted EBITDA Margin.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While revenue growth is strong and a share repurchase program is in place, there are concerns about gross margin and net income decline. The future outlook is reiterated, providing some stability.

Positives

• Dexcom achieved strong revenue growth in Q1 2025.
• The company expanded coverage in the US with major PBMs.
• The launch on the Amazon storefront expands Stelos distribution footprint.
• FDA clearance for the Dexcom G7 15 Day System was received.
• The share repurchase program can return value to shareholders.
• Dexcom has a strong cash position of $2.70 billion.

Negatives

• Non-GAAP operating income decreased by 140 basis points compared to Q1 2024.
• GAAP gross profit decreased from 61.0% to 56.9% of revenue.
• Non-GAAP gross profit decreased from 61.8% to 57.5% of reported revenue.
• GAAP net income decreased from $146.4 million to $105.4 million.
• Hardware revenue decreased 42% year-over-year.

Risks

• Incremental costs related to near-term supply dynamics are impacting the Non-GAAP Gross Profit Margin.
• The timing of share repurchases depends on market conditions and is at Dexcom's discretion.
• The share repurchase program does not obligate Dexcom to repurchase any specific dollar amount or number of shares.

Future Outlook

Dexcom is updating fiscal year 2025 guidance for Non-GAAP Gross Profit Margin, and reiterating guidance for Revenue, Non-GAAP Operating Margin, and Adjusted EBITDA Margin.

Management Comments

• To start the year, Dexcom delivered a quarter of strong revenue results and unlocked significant new type 2 coverage, said Kevin Sayer, Dexcoms chairman, president and CEO.
• As we progress through 2025, we will advance our product portfolio with the launch of our Dexcom G7 15 Day system and continue to advocate for expanded global access to our glucose biosensors.

Industry Context

Dexcom's results reflect the growing demand for continuous glucose monitoring (CGM) technology in diabetes management. The expansion of coverage by PBMs and the launch of new products like the G7 15 Day System position Dexcom to compete effectively in the market.

Comparison to Industry Standards

• Dexcom's revenue growth of 12% is comparable to other companies in the medical device and diabetes care space.
• For example, Medtronic's diabetes group saw a decline in revenue in their most recent quarter, while Abbott's diabetes care segment continues to show strong growth.
• Dexcom's gross margin is lower than some competitors, which may be due to supply chain issues and product mix.
• Companies like Insulet, which focuses on insulin pumps, have different financial profiles due to the nature of their products and services.

Stakeholder Impact

• Shareholders may benefit from the share repurchase program.
• Customers will have access to new products like the Dexcom G7 15 Day System.
• Employees may be impacted by business transition and related costs.

Next Steps

• Dexcom will continue to advance its product portfolio with the launch of the Dexcom G7 15 Day system.
• Dexcom will continue to advocate for expanded global access to its glucose biosensors.
• Dexcom will execute the $750 million share repurchase program.

Key Dates

Keywords

Dexcom, financial results, share repurchase program, CGM, revenue, diabetes, G7, FDA clearance, gross profit, operating income, net income